贝伐珠单抗在非小细胞肺癌中应用的研究现状

Current Indication of Bevacizumab Treatment for Non-Small Cell Lung Cancer

Peking University School of Oncology, Beijing Cancer Hospital and Institute, Key Laboratory of Carcinogenesis and Translational Re-search (Ministry of Education), Beijing 100142, China

摘要: 目前非小细胞肺癌化疗疗效已经达平台期，亟需寻找新的方法提高疗效。贝伐珠单抗是一种重组抗VEGF单克隆抗体，是首个证实与化疗联合可提高晚期NSCLC 患者生存的靶向治疗药物。近年来许多关于贝伐珠单抗在NSCLC 一线、二线、辅助、新辅助治疗、联合放化疗，安全性及预测标志物的临床研究，现将其研究现状做一综述。
- 贝伐珠单抗 /
- 非小细胞肺癌 /
- 有效性 /
- 安全性 /
- 预测因子
Abstract: At present, chemotherapy for non-small cell lung cancer (NSCLC) has reached a therapeutic plateau; new treatment options are needed to improve efficacy. Bevacizumab is a vascular endothelial growth factor monoclonal antibody. It is the first targeted therapy confirmed to improve the chemotherapy survival in advanced NSCLC. Many clinical studies about bevacizumab as first-line, second-line, adjuvant, and neoadjuvant treatments with chemoradiation are ongoing. The article reviews the current indications for beva -cizumab.
- Bevacizumab /
- NSCLC /
- Efficacy /
- Safety /
- Predictive marker